CCI Gives Approval To Carlyle Group's 20% Buy In Piramal Pharma
The Competition Commission of India (CCI) on Friday said it had approved acquisition of 20 per cent stake in Ajay Piramal-led Piramal Pharma by US-based global investment firm Carlyle Group.
Piramal Enterprises, in a regulatory filing, in June had said Carlyle Group Inc would buy 20 per cent stake in Piramal Pharma for around $490 million (over Rs 3,700 crore).
The estimated equity capital investment for Carlyle's 20 per cent stake in Piramal Pharma would amount to around $490 million, it said.
The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal, it said.
Central Banks And The Economic Horizon: Steering Through Uncertaintie
In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more
Transforming Financial Operations With Robotic Process Automation
Author: Ricardo Goulart ... Read more
The Role Of Machine Learning In Fraud Detection
Author: Gerardine Lucero  ... Read more
Principles Of Islamic Banking And Finance
When it comes to banking, a significant new contender has entered the ring. The principles of Islamic banking and financ... Read more
The Role Of Central Banks In Global Economy
The role of central banks in global economy is a stimulating topic that requires profound understanding. Commonly, centr... Read more
History Of Banking Evolution In The 21st Century
Throughout time, the banking sector has assumed a central role in the smooth functioning of economies, generating growth... Read more